Clinical Outcome and Drug Expenses of Intravitreal Therapy for Diabetic Macular Edema: A Retrospective Study in Sardinia, Italy.
adverse drug reactions
best corrected visual acuity
central retinal thickness
diabetic macular edema
intravitreal agents
intravitreal drug expenses
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
16 Nov 2021
16 Nov 2021
Historique:
received:
29
10
2021
revised:
12
11
2021
accepted:
14
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
Diabetic macular edema (DME) is a leading cause of visual loss in working-age adults. The purpose of this retrospective study was to perform an epidemiological analysis on DME patients treated with intravitreal drugs in a tertiary hospital. The clinical outcome, adverse drug reactions (ADRs), and intravitreal drug expenses were assessed. All DME patients treated with Ranibizumab, Aflibercept, Dexamethasone implant, and Fluocinolone Acetonide implant at the Sassari University Hospital, Italy, between January 2017 and June 2020 were included. Central macular thickness (CMT) and best corrected visual acuity (BCVA) were measured. ADRs and drug expenses were analyzed. Two-hundred thirty-one DME patients (mean age: 65 years) received intravitreal agents. Mean CMT and BCVA were 380 μm and 0.5 LogMAR at baseline, 298 μm and 0.44 logMAR after one year ( Results confirm that Ranibizumab, Aflibercept, and Dexamethasone implant are effective and safe in DME treatment. A switch to Dexamethasone implant for patients receiving Aflibercept or Ranibizumab with minimal/no clinical benefit should be considered.
Sections du résumé
BACKGROUND
BACKGROUND
Diabetic macular edema (DME) is a leading cause of visual loss in working-age adults. The purpose of this retrospective study was to perform an epidemiological analysis on DME patients treated with intravitreal drugs in a tertiary hospital. The clinical outcome, adverse drug reactions (ADRs), and intravitreal drug expenses were assessed.
METHODS
METHODS
All DME patients treated with Ranibizumab, Aflibercept, Dexamethasone implant, and Fluocinolone Acetonide implant at the Sassari University Hospital, Italy, between January 2017 and June 2020 were included. Central macular thickness (CMT) and best corrected visual acuity (BCVA) were measured. ADRs and drug expenses were analyzed.
RESULTS
RESULTS
Two-hundred thirty-one DME patients (mean age: 65 years) received intravitreal agents. Mean CMT and BCVA were 380 μm and 0.5 LogMAR at baseline, 298 μm and 0.44 logMAR after one year (
CONCLUSION
CONCLUSIONS
Results confirm that Ranibizumab, Aflibercept, and Dexamethasone implant are effective and safe in DME treatment. A switch to Dexamethasone implant for patients receiving Aflibercept or Ranibizumab with minimal/no clinical benefit should be considered.
Identifiants
pubmed: 34830624
pii: jcm10225342
doi: 10.3390/jcm10225342
pmc: PMC8619487
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Surv Ophthalmol. 2009 Jan-Feb;54(1):1-32
pubmed: 19171208
Int J Mol Sci. 2018 Jun 20;19(6):
pubmed: 29925789
Arch Ophthalmol. 1984 Apr;102(4):527-32
pubmed: 6367725
BMC Ophthalmol. 2018 Apr 12;18(1):91
pubmed: 29649995
Curr Opin Ophthalmol. 2017 Jan;28(1):23-28
pubmed: 27661663
Diabetes Care. 2013 Jan;36 Suppl 1:S11-66
pubmed: 23264422
Arch Ophthalmol. 1989 Feb;107(2):237-43
pubmed: 2916977
Arch Ophthalmol. 1989 Feb;107(2):244-9
pubmed: 2644929
Front Pharmacol. 2021 Apr 12;12:670468
pubmed: 33912065
Diabetes Care. 2003 Sep;26(9):2653-64
pubmed: 12941734
Invest Ophthalmol Vis Sci. 2008 May;49(5):2030-8
pubmed: 18436837
Cochrane Database Syst Rev. 2011 Jul 06;(7):CD008081
pubmed: 21735421
Curr Opin Ophthalmol. 2009 Nov;20(6):511-9
pubmed: 19667987
Ophthalmology. 2020 Jan;127(1):P66-P145
pubmed: 31757498
Dev Ophthalmol. 2014;54:164-73
pubmed: 25196766